NCT01037036

A Study of the L-PPDS With Adjunctive Xalatan® Eye Drops in Subjects With OH or OAG

An Open-Label, Phase 2 Study of the Latanoprost Punctal Plug Delivery System (L-PPDS) With Adjunctive Xalatan® Eye Drops in Subjects With Ocular Hypertension (OH) or Open-Angle Glaucoma (OAG)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 15 (actual)
• Sponsor: Mati Therapeutics Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The objective of this study is to investigate how the intraocular pressure (IOP)-lowering effect of the L-PPDS is altered by adjunctive Xalatan therapy.

Conditions

• Ocular Hypertension
• Open-Angle Glaucoma

Interventions

Type	Name	Description
DRUG	Latanoprost Punctal Plug Delivery System	To evaluate the control of IOP compared to baseline, for an experimental dose of Latanoprost Punctal Plug Delivery System for 4 week or until loss of efficacy. This is a single arm study.
DRUG	Xalatan	Subjects will administer adjunctive Xalatan eye drops once daily for 2 weeks. This is a single arm study.

Timeline

• Start date: 2009-12-01
• Primary completion: 2010-04-01
• Completion: 2010-07-01
• First posted: 2009-12-21
• Last updated: 2014-01-10

Locations

1 site across 1 country: United States